A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)
Phase: PHASE3
Conditions: Female Infertility
Sponsor: Abbott

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 1 of 54
CLINICAL STUDY PROTOCOL
WORKING PROTOCOL INCLUDING AMENDMENT 01, 02 and 03
Cover Page
Protocol No.:
M13-625
Protocol Date:
Amendment 01:
Amendment 02:
Amendment 03:
19 June 2013
31 March 2015
7 September 2015
4 January 2016
Study Title:
A Randomized, Open-label, Two-arm, Multicenter Study 
Comparing the Efficacy, Safety and Tolerability of Oral 
Dydrogesterone 30 mg daily versus Crinone 8% intravaginal 
progesterone gel 90 mg daily for Luteal Support in In-Vitro 
Fertilization (LOTUS II)
IND No.:
EudraCT No.:
2012-002993-29
Phase of Development:
III
Sponsor:
Abbott Laboratories GmbH
Freundallee 9A
D-30173 Hannover
Global Clinical Director / 
Strategic Medical Affairs 
Medical Director / Head 
Clinical Pharmacology:
Protocol Author(s): 
 
 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 2 of 54
SYNOPSIS
Name of Sponsor:
Abbott Laboratories
Name of Finished Product:
Duphaston®
Name of Active Ingredient(s):
Dydrogesterone
Title of Study:
A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and 
Tolerability of Oral Dydrogesterone 30 mg daily versus Crinone 8% intravaginal progesterone gel 90 
mg daily for Luteal Support in In-Vitro Fertilization
Study Center(s) (Planned):
Approximately 30 to 40 study sites
Study Duration:
The planned study period from First Subject First Visit until 
Last Subject Last Visit is August 2015 until April 2017 (End 
of Study is defined as Last Subject Last Visit.) The treatment 
phase is up to 12 weeks of gestation with an observation phase 
until 1 month after delivery.
Phase of Development:
III
Objectives:
– Efficacy Objectives: The primary objective is to demonstrate non-inferiority of oral 
dydrogesterone versus micronized progesterone as vaginal gel. The primary efficacy parameter is 
the presence of fetal heart beats at 12 weeks’gestation (10 weeks´ pregnancy) determined by 
transvaginal ultrasound. The secondary parameters are a positive pregnancy test on Day 14 after 
embryo transfer and the incidence of live births and healthy newborn(s).
– Safety and Tolerability Objectives: To obtain safety and tolerability data by means of 
documentation of treatment emergent adverse events (TEAE) during the entire study period. In 
addition, data on vital signs, physical examination findings, and routine laboratory values will be 
obtained. Furthermore, signs and symptoms of threatened abortion will be recorded. The time of 
delivery (pregnancy week) and the following parameters of the newborn (s) will be obtained at 
delivery: gender, APGAR Score, weight, height, head circumference, abnormal findings of 
physical examination and any malformations.
This is a prospective randomized, open-label, two-arm, multicenter study comparing the efficacy, 
safety and tolerability of the oral dydrogesterone treatment regime versus an intravaginal micronized 
progesterone gel treatment for the luteal support in in-vitro fertilization (IVF).
The study will be conducted according to the following scheme:
1. Screening and Enrollment (Day -40 to -1 [day of downregulation/ ovarian follicle stimulation], 
Visit 1): Subjects signing the informed consent form will be evaluated for eligibility. They will 
undergo a physical examination including vital signs; a review of their medical history and 
concomitant medication. A transvaginal ultrasound will be done, if the last transvaginal 
examination is older than 14 days. Blood samples will be taken for baseline routine laboratory 
values and in addition, for subjects where the following hormone values, FSH, estradiol (E2) LH 
(luteinizing hormone), PRL (Prolactin), T (testosterone) and TSH (thyroid-stimulating hormone), 
are not available prior screening, a hormone testing should be performed.
2. Treatment period (Day 0 to Week 10): Luteal support starts on Day 0 (Visit 2), the day of oocyte 
retrieval. Subjects will be treated with one of the following treatment regimens:

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 3 of 54
Name of Sponsor:
Abbott Laboratories
Name of Finished Product:
Duphaston®
Name of Active Ingredient(s):
Dydrogesterone
Group I
Oral Dydrogesterone 10 mg tablets three times daily (tid)
or
      Group II
Crinone 8% intravaginal progesterone gel 90 mg once daily 
3. At Visit 3 (Day 2-5): The day of embryo transfer, this interventional procedure is following the 
clinic specific IVF protocol. 
4. At Visit 4 (Day 16-19 days). On day 14 after embryo transfer, subjects will have a routine 
pregnancy test (serum β-HCG) to confirm subject’s biochemical pregnancy. If the test is positive, 
luteal support treatment is continued up to week 10 pregnancy (week 12 of gestation).
If pregnancy is not confirmed on Visit 4 the early discontinuation visit should be performed 
including physical examination and vital signs. Blood samples will be taken for routine laboratory 
values. 
5. At Visit 5 (Day 42 + /- 3 days – Week 6): Study medication packages should be returned. If 
pregnancy is confirmed according to clinical evidence then the new study medication packages 
will be dispensed. Pregnancy related TEAEs and concomitant medication will be recorded.
If an event of miscarriage occurs between the Visits 4 and 6, subject should return to the study 
site for the early discontinuation visit within 30 days of the last treatment dose or keep their 
appointment for Visit 6, whichever occurs first. A physical examination including vital signs will 
be performed; blood samples will be taken for routine laboratory values. Concomitant 
medication and any TEAEs will be recorded; the subject will return the remaining study 
medication.
6. End of treatment on Visit 6 (Day 70 (+ /-3 days)-Week 10): A transvaginal ultrasound 
examination will be performed to confirm ongoing pregnancy defined as the presence of fetal 
heart beats. Data on vital signs, routine laboratory values, TEAEs, and concomitant medication 
will be recorded. Subjects return their study medication.
7. Post treatment surveillance calls (Visit 7 and 8): Subjects will be followed during the pregnancy 
by routine pregnancy supervision program until the date of delivery. In addition 2 telephone calls 
(on Day 100 +/- 3 days and on Day 156 +/-3 days)) will be done to record any concomitant 
treatment and medications and any TEAEs. Especially events of miscarriage and preterm delivery 
will be recorded. 
8. After successful delivery (Visit 9), the time of delivery (pregnancy week) and the following 
parameters of the newborn(s) will be obtained: gender, APGAR Score, weight, height, head 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 4 of 54
Name of Sponsor:
Abbott Laboratories
Name of Finished Product:
Duphaston®
Name of Active Ingredient(s):
Dydrogesterone
circumference, abnormal findings of physical examination and any malformations.
9. At Visit 10 (Day 30 +/- 3 days after delivery): A phone call will be performed to record both 
mother’ and newborn’s safety and wellbeing. 
Number of Subjects (Planned):
Number of subjects to be allocated to treatment:  1066
Number of subjects to be screened:  1250
Diagnosis and Main Criteria for Inclusion:
Inclusion Criteria:
– Signed informed consent
– Premenopausal females, age > 18 years < 42 years
– Non-smokers. For females who were past smokers, they must have stopped tobacco usage for at 
least 3 months prior screening visit
– Early follicular phase (Day 2-4) FSH (Follicle stimulating hormone) less than or equal to 15 IU/L 
and estradiol (E2) within normal limits at screening
– LH (luteinizing hormone), PRL (prolactin), T (testosterone) and TSH (thyroid-stimulating 
hormone), within the normal limits for the clinical laboratory, or considered not clinically 
significant by the Investigator within 6 months prior or at screening
– Documented history of infertility (e.g., unable to conceive for at least one year or for 6 months for 
women ≥ 38 years of age or bilateral tubal occlusion or absence)
– Normal transvaginal ultrasound at screening (or within 14 days prior of screening) without 
evidence of clinically significant abnormality consistent with finding adequate for ART with 
respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine fibroids)
– Subject is not pregnant, confirmed by negative pregnancy test or by investigator judgment 
– Clinical indicated protocol for induction of IVF with a fresh embryo
– Single or dual embryo transfer
– BMI ≥18 and ≤ 30 kg/m2
Test Product, Dose and Mode of Administration:
Dydrogesterone 10 mg oral tablets three times daily (tid)
Duration of Treatment:
The treatment duration is 10 weeks plus a safety follow-up.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 5 of 54
Name of Sponsor:
Abbott Laboratories
Name of Finished Product:
Duphaston®
Name of Active Ingredient(s):
Dydrogesterone
Reference Therapy, Dose and Mode of Administration:
Crinone 8% intravaginal progesterone gel 90 mg daily.
Criteria for Evaluation:
Efficacy:
The primary efficacy parameter is the pregnancy rate defined as the presence of fetal heart beats at 12 
weeks’ gestation determined by transvaginal ultrasound. The secondary parameters are a positive 
pregnancy test on Day 14 after embryo transfer and the incidence of live births and healthy newborns.
Safety:
Safety and Tolerability Criteria: To obtain safety and tolerability data by means of documentation of 
treatment emergent adverse events (TEAE) during the entire study period. In addition, data on vital 
signs, physical examination findings, and routine laboratory values will be obtained. Furthermore, 
signs and symptoms of threatened abortion will be recorded. The time of delivery (pregnancy week) 
and the following parameters of the newborn baby will be obtained at delivery: gender, APGAR 
Score, weight, height, head circumference, abnormal findings of physical examination and any 
malformations. A phone call 30 days after delivery to establish both mother’ and newborn’s safety 
and wellbeing.
Statistical Methods:
Efficacy:
The primary endpoint is the comparison of ongoing pregnancy rates between the active comparator 
and the dydrogesterone treatment regime. 
The primary efficacy analysis is using a two-sided 95% confidence interval with a non-inferiority 
margin of 10% for the pregnancy rates in the two treatment groups. The dydrogesterone group will be 
compared against intravaginal micronized progesterone gel. So in order to declare non-inferiority, the 
lower bound of the two-sided 95% confidence interval should exclude a difference greater than 10% 
in favor of the comparator. In order to calculate the confidence intervals a Cochran-Mantel-Haenszel 
test stratified for country and age groups will be used. Two age groups will be defined, subjects older 
or younger than 35 years. 
For the primary efficacy analysis, the full analysis FA sample will be used. In addition, further 
statistical tests may be performed, also on secondary variables. All efficacy and safety parameters will 
be summarized by standard descriptive methods.
Safety:
The safety sample will be used for the analysis of the safety and tolerability data. Safety variables will 
be summarized by standard descriptive statistics.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 6 of 54
Name of Sponsor:
Abbott Laboratories
Name of Finished Product:
Duphaston®
Name of Active Ingredient(s):
Dydrogesterone
Treatment emergent AEs are summarized by unique treatment. Severity and drug-event relationship 
of treatment emergent AEs are summarized separately.
Laboratory variables, including changes from baseline will be summarized. A frequency table will be 
presented for markedly abnormal values. Shift tables will be presented according to the reference 
ranges (low, normal or high).
Vitals signs, including changes from baseline will be summarized. A frequency table will be 
presented for markedly abnormal values.
Sample size
Several studies can be found in literature investigating the use of dydrogesterone, intravaginal 
micronized progesterone capsules (Utrogestan®) or micronized progesterone gel (Crinone®) treatment 
in IVF. The following table displays the 8- or 12-week pregnancy rate for several studies.
The largest study from Ganesh et al. showed comparable results for micronized progesterone gel and 
dydrogesterone and only a small, non-significant difference in rates between dydrogesterone and 
micronized progesterone capsules. Both the study from Kleinstein and Ludwig conclude that both 
micronized progesterone gel and micronized progesterone capsules will give similar results. 
Therefore, it is assumed that dydrogesterone and micronized progesterone gel will have similar results 
with about 35% pregnancy rate at week 12.
A non-inferiority margin of 10% was chosen based on data from the previously approved 
8-week pregnancy rate
12-week pregnancy rate
Dydro-
gesterone
Intravaginal 
micronized 
progesterone 
capsules
micronized 
progesterone 
gel
Dydro-
gesterone
Intravaginal 
micronized 
progesterone 
capsules
micronized 
progestero
ne gel
Ganesh 20113
29% 
(121/422)
23% 
(104/459)
29% 
(138/482)
Patki 200710
41% 
(150/366)
30% (91/309)
Kleinstein 
200511
25% (55/218)
22% 
(47/121)
Tomic 201112
33% 
(62/185)
Simunic 200713
30% (42/136)
33% 
(43/130)
Ludwig 200214  
17% (9/53)
25% 
(18/73)
Baruffi 200315
28% (29/103)
Pouly 199616
25% (36/144)
29% 
(40/139)
Lutinus/Endome
trin program 
2006 17
42.3 % 
(171/404)
42.2% 
(170/403)

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 7 of 54
Name of Sponsor:
Abbott Laboratories
Name of Finished Product:
Duphaston®
Name of Active Ingredient(s):
Dydrogesterone
Lutinus®/Endometrin® drug.
Assuming a 35% pregnancy rate for the dydrogesterone and the micronized progesterone gel study 
group, a sample size of about 479 subjects per group would provide 90% power to reject the null 
hypothesis of H0: pdydro – pprogesterone ≤ -0.1 in favor of the alternative: H1: pdydro – pprogesterone > -0.1 with 
a one-sided significance level of 2.5%.
Assuming a dropout rate of 10%, a total sample size of 533 subjects per treatment group would be 
required, resulting in a total sample size of 1066 subjects in order to show non inferiority in the 
primary efficacy parameter.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 8 of 54
TABLE OF CONTENTS
SYNOPSIS................................................................................................................................2
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS.......................................11
1
ETHICS ..........................................................................................................................14
1.1
Independent Ethics Committee or Institutional Review Board ...................................14
1.2
Ethical Conduct of the Study.......................................................................................14
1.3
Subject Information and Consent.................................................................................15
2
INTRODUCTION..........................................................................................................16
3
STUDY OBJECTIVES..................................................................................................18
3.1
Primary Objective(s)....................................................................................................18
3.2
Secondary Objective(s)................................................................................................18
3.3
Safety Objective(s).......................................................................................................18
4
STUDY DESIGN............................................................................................................19
4.1
Overall Study Design and Plan-Description................................................................19
4.2
Discussion of Study Design, Including the Choice of Control Groups.......................20
5
SELECTION OF STUDY POPULATION .................................................................21
5.1
Inclusion Criteria .........................................................................................................21
5.2
Exclusion Criteria ........................................................................................................21
5.3
Rationale for Diagnosis and Criteria............................................................................22
6
REMOVAL OF SUBJECTS FROM THERAPY OR ASSESSMENT.....................23
7
TREATMENTS..............................................................................................................24
7.1
Treatments to be administered.....................................................................................24
7.2
Packaging and Labeling...............................................................................................24
7.3
Storage and Dispensing of Study Drug........................................................................24
7.4
Method of Assigning Subjects to Treatment Groups...................................................25
7.5
Selection of Doses in the Study...................................................................................25
7.6
Selection and Timing of Dose for Each Subject..........................................................25
7.8 
  Prior and Concomitant Therapy.................................................................................25
7.9
   Treatment Compliance..............................................................................................25
8
STUDY ASSESSMENTS AND FLOW CHART........................................................27
8.1
Efficacy Measurements................................................................................................27

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 9 of 54
8.2
Safety Measurements...................................................................................................27
8.3
Other Assessments.......................................................................................................28
8.4
Appropriateness of Measurements...............................................................................29
8.5
Primary Efficacy Variable ...........................................................................................29
8.6
Flow Chart of Study Assessments ...............................................................................29
9
ADVERSE EVENTS .....................................................................................................33
9.1
Adverse Events and Adverse Drug Reactions .............................................................33
9.1.1
Recording of Adverse Events ..................................................................................33
9.1.2
Follow-up of Adverse Events ..................................................................................35
9.2
Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions (SADRs).......35
9.2.1
Reporting Serious Adverse Events ..........................................................................36
9.2.2
Reporting of Suspected Unexpected Serious Adverse Drug Reactions (SUSARs) to 
Regulatory Authorities and Investigators ................................................................36
9.2.3
Reporting of Pregnancy Adverse Event/Outcome...................................................37
10
STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE.........38
10.1
General Definitions and Conventions..........................................................................38
10.2
Subject Samples...........................................................................................................39
10.3
Efficacy........................................................................................................................40
10.4
Safety ...........................................................................................................................41
10.5
Other Assessments.......................................................................................................42
10.6
Subgroup Analysis.......................................................................................................42
10.7
Interim Analysis...........................................................................................................42
10.8
Determination of Sample Size .....................................................................................42
11
INVESTIGATOR OBLIGATIONS.............................................................................44
11.1
Essential Study Documents..........................................................................................44
11.2
Case Report Form (CRF) Completion.........................................................................44
11.3
Essential Records Retention ........................................................................................46
11.4
Investigator Agreement................................................................................................46
12
SPONSOR OBLIGATIONS .........................................................................................48
12.1
Protocol Amendments..................................................................................................48
12.2
Study Monitoring.........................................................................................................48
12.3
Quality Assurance Audits ............................................................................................49
13
PUBLICATION POLICY.............................................................................................50
14
INSURANCE..................................................................................................................51
15
REFERENCES...............................................................................................................52

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 10 of 54
16
APPENDICES................................................................................................................54
16.1
Appendix – Participating Countries’ National Insurance Requirements.....................54
16.2
Appendix – Coordinating Investigator Signature of Clinical Study Report................54
LIST OF IN-TEXT TABLES
Table 1. Flow Chart of Study Assessments .............................................................................30

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 11 of 54
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
ADR
adverse drug reaction
AE
adverse event
APGAR  score assessing the health of newborn, done one and five minutes after birth (heart 
rate, skin color, reflex irritability, muscle tone, respiratory effort) 
ATC
Anatomical Therapeutic Chemical
ART
Assisted Reproductive Technology
Beta-hCG human chorionic gonadotropin
CFR
Code of Federal Regulations
CRF
case report form (paper or other media)
Ctrough
observed predose (trough) plasma concentration
CV
coefficient of variation
CYP
cytochrome P450
DHEA-S
Dehydroepiandrosterone sulfate
DBP
diastolic blood pressure
DMC
Data Monitoring Committee
E2
estrogen
ECG
electrocardiogram
EDC
Electronic Data Capture
EEG
electroencephalogram
EU
European Union
EudraCT
European clinical trials database
FA
full analysis
FDA
Food and Drug Administration
FSH
follicle stimulating hormone

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 12 of 54
GCP
Good Clinical Practice
GMP
Good Manufacturing Practice
GPRM
Global Pharmacovigilance and Risk Management 
HLGT
high level group term
HLT
high level term
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation 
IEC
Independent Ethics Committee
IMP
Investigational Medicinal Product
IND
Investigational New Drug
IRB
Institutional Review Board
IVF
in vitro fertilization
IRT
Interactive Response Technology
LH
luteinizing hormone
LPD
luteal phase deficiency 
LLOQ
lower limit of quantification
LLT
lowest level term
Max
Maximum
MedDRA Medical Dictionary for Regulatory Activities
Min
Minimum
MRT
mean residence time
N/A
not applicable
PD
pharmacodynamic
PK
pharmacokinetic

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 13 of 54
PP
per-protocol
PT
preferred term
PTF
peak trough fluctuation
SADR
serious adverse drug reaction
SAE
serious adverse event
SBP
systolic blood pressure
SD
standard deviation
SOC
system organ class
SPC
Summary of Product Characteristics
SUSAR
suspected unexpected serious adverse drug reaction
TEAE
treatment emergent adverse event
TSH
Thyroid-stimulating hormone
WHO
World Health Organization

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 14 of 54
1
ETHICS
1.1
Independent Ethics Committee or Institutional Review Board
The Sponsor (or an authorized representative) or the Investigator (according to national 
provisions) is responsible for obtaining written approval for the clinical study protocol 
(including all substantial protocol amendments), the written subject informed consent form 
(including written assent, when applicable), informed consent updates, subject recruitment 
procedures (e.g., advertisements) and any other written information to be provided to 
subjects from an Independent Ethics Committee (IEC) / Institutional Review Board (IRB) 
that complies with the local regulatory requirements.
Written approval of the study must be obtained from the IEC/IRB prior to the study being 
implemented (i.e., shipment of clinical supplies to the Investigator or screening of subjects). 
Copies of the approval documentation will be maintained by both the Investigator and the 
Sponsor (or an authorized representative) in the designated study documentation files.
The Sponsor (or an authorized representative) or the Investigator (according to national 
provisions) will submit written reports of the clinical study status to the IEC/IRB annually, or 
more frequently if requested by the IEC/IRB. A final study notification should be forwarded 
to the IEC/IRB within 90 days after the study has completed, or in the event of premature 
termination of the study, within 15 days with the rationale for study termination clearly 
explained. Copies of all clinical study status reports (including termination) will be 
maintained by both the Investigator and the Sponsor (or an authorized representative) in the 
study documentation files.
In accordance with national provisions and the rules of the EU Clinical Trial Directive, the 
Sponsor (or an authorized representative) will inform all participating IECs/IRBs and 
national authorities of all SAEs/SADRs/SUSARs or other safety-related information, which 
occur during the clinical study.
1.2
Ethical Conduct of the Study
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting studies that involve the participation of 
human subject. The study will be conducted in compliance with GCP and the applicable 
national regulations to assure that the rights, safety, and well-being of the participating study 
subjects are protected consistent with the ethical principles that have their origin in the 
Declaration of Helsinki. 
Data Monitoring Committee
Not applicable

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 15 of 54
1.3
Subject Information and Consent
Voluntary written informed consent will be obtained from each subject prior to performing 
any study-related procedures. Each subject will be given both verbal and written information 
describing the nature and duration of the clinical study. The informed consent process will 
take place under conditions where the subject has adequate time to consider the risks and 
benefits associated with his/her participation in the study. Subjects will not be screened or 
treated until the subject has signed an approved informed consent written in a language that 
is understandable to the subject.
The IEC/IRB approved informed consent form will be signed and personally dated by the 
subject (or legally acceptable representative, when appropriate) and the person who 
conducted the informed consent discussion. Each subject is to receive a copy of the signed 
and dated written informed consent form and any other written subject information.
The signature of an impartial witness is to be obtained in the event the subject or the 
subject’s legally acceptable representative is unable to read. Additional signatures on the 
informed consent form may be required in accordance with IEC/IRB requirements or those 
of the Sponsor (or an authorized representative).
The Investigator is responsible for assuring the appropriate content of the informed consent 
form and that informed consent is obtained from each subject in accordance with the 
applicable regulations and guidelines. The original signed informed consent is to be retained 
in the study documentation files.
The Investigator shall maintain a log of all subjects who sign the informed consent form and 
indicate if the subject received study drug or, if not, the reason why. The subject´s medical 
records should also document that the informed consent form was signed and dated prior to 
any study-related procedures being performed.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 16 of 54
2
INTRODUCTION
Assisted reproductive technology (ART) is a general term referring to methods to achieve 
pregnancy by artificial or partial artificial means. Technically, the term ART refers only to 
fertility treatments, such as in vitro fertilization (IVF) and its variants (e.g., intracytoplasmic 
sperm injection (ICSI), frozen embryo replacement (FER), egg donation (ED) etc.). More 
than 4 million babies have been conceived by ART methods since the birth of the first IVF 
baby Louise Brown in 1978 (EIM Consortium 2010).
Most assisted reproductive technologies procedures use in-vitro fertilization (IVF).
As part of the Assisted Reproductive Therapy procedures (ART), gonadotroping releasing 
hormones (GnRH) are used to induce ovarian stimulation. The use of GnRHs causes a 
suppression of luteinizing hormone (LH) secretion, which results in a dysfunctional corpus 
luteum and leads to inadequate ovarian progesterone production. Low progesterone levels 
lead to an incomplete secretory endometrium and ineffective ovum implantation. Luteal 
deficiency was first proposed as a cause of infertility in 1949.2
The modulating effect of progesterone on endometrial structure and function are essential for 
the success of human reproduction. After ovulation, progesterone produced by the corpus 
luteum induces secretory maturation of the endometrium, involving a cascade of molecular 
events that ultimately renders the endometrium receptive to implantation of the embryo. 
After nidation, continued progesterone stimulation, driven by rapidly increasing 
concentration of hCG, decidualizes the endometrial stoma and supports early embryonic 
development. 
Progesterone or hCG treatment has become an established supplement to support the corpus 
luteum progesterone production, to support the luteal phase of the artificial cycle, promote 
the maintenance of the endometrium and enhance the likelihood of implantation of a 
fertilized egg.
The luteal support causes a considerable improvement in the pregnancy rates as compared to 
IVF cycles without luteal support.3,4
Progesterone has become the agent of choice for luteal support because hCG is associated 
with a higher risk of ovarian hyperstimulation syndrome (OHSS), particulary in younger 
women, good responders, and women with polycystic ovary syndrome.
The evidence for the beneficial use of progesterone and other progestogens in LPD is largely 
empirical. 5 The range of success rates is between 30 and 60%.6,7 The low success rates in 
some publications may at least partly be explained by the poor selection of cases with the 
diagnosis of luteal deficiency made in a haphazard manner. In addition, the doses might not 
always have been high enough. 
When progestogene supplementation is the therapy of choice in luteal support, 
dydrogesterone is frequently used in infertility as it has no inhibitory effect on ovulation, it 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 17 of 54
does not inhibit the formation of progesterone in human placenta during early pregnancy, and 
does not cause masculinization of the fetus.8,9
In most ART centers worldwide the use of micronized progesterone, as vaginal gel 
formulation, has become a routine practice. The usual dose for luteal-phase support with the 
micronized progesterone gel is 90 mg once daily. 
The main side effects associated with vaginal preparation are vaginal irritation, discharge, 
and dyspareunia. Several research groups believe that due to the local side effects the vaginal 
application is not very well accepted by all subjects. 
Dydrogesterone, a retroprogesterone derivate, has a good bioavailability combined with all of 
the clinical properties of endogenous progesterone, as well as being devoid of local side 
effects. Dydrogesterone has been used effectively in various gynecological disease, e.g. 
premenstrual disease, endogenous progesterone deficiency, menstrual abnormalities, 
endometriosis and in combination with estrogen in hormone replacement therapy.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 18 of 54
3
STUDY OBJECTIVES
3.1
Primary Objective(s)
The primary objective is to demonstrate non-inferiority of oral dydrogesterone versus 
micronized progesterone as vaginal gel. The primary efficacy parameter is the presence of 
fetal heart beats at 12 weeks’ gestation determined by transvaginal ultrasound.
3.2
Secondary Objective(s)
The secondary objectives and parameters are a positive pregnancy test on Day 14 after 
embryo transfer and the incidence of live births and healthy newborns.
3.3
Safety Objective(s)
The safety objective is to obtain safety and tolerability data by means of documentation of 
treatment emergent adverse events (TEAE) during the entire study period. In addition, data 
on vital signs, physical examination findings, and routine laboratory values will be obtained. 
Furthermore, signs and symptoms of threatened abortion will be recorded. The time of 
delivery (pregnancy week) and the following parameters of the newborn will be obtained at 
delivery: gender, APGAR Score, weight, height, head circumference, abnormal findings of 
physical examination and any malformations.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 19 of 54
4
STUDY DESIGN
4.1
Overall Study Design and Plan-Description
This is a prospective open label, randomized, two-arm, multicenter study comparing the 
efficacy, safety and tolerability of the oral dydrogesterone treatment regimen versus an 
intravaginal micronized progesterone gel treatment for the luteal support in in-vitro
fertilization (IVF).
The study will be conducted according to the following scheme: 
•
Screening and Enrollment (Day -40 to -1 [day of downregulation/ovarian follicle 
stimulation], Visit 1): Subjects signing the informed consent form will be evaluated for 
eligibility. They will undergo a physical examination including vital signs; a review of 
their medical history and concomitant medication. A transvaginal ultrasound will be 
done, if the last transvaginal examination is older than 14 days. Blood samples will be 
taken for baseline routine laboratory values and in addition, for subjects where the 
following hormone values, FSH, estradiol (E2), LH (luteinizing hormone), PRL 
(Prolactin), T (testosterone) and TSH (thyroid-stimulating hormone), are not available 
prior screening, a hormone testing should be performed.
•
Treatment period (Day 0 to Week 10): Luteal support starts on Day 0 (Visit 2), the day of 
oocyte retrieval. Subjects will be treated with one of the following treatment regimens:
Group I
Oral Dydrogesterone 10 mg tablets three times daily (tid)
or
Group II
Crinone 8%, intravaginal progesterone gel 90 mg, once daily 
•
At Visit 3 (Day 2 - 5): The day of embryo transfer, this interventional treatment is 
following the clinic specific IVF protocol.
•
At Visit 4 (Day 16 - 19 days). On day 14 after embryo transfer, subjects will have a 
routine pregnancy test (serum β-hCG) to confirm subject´s biochemical pregnancy. If the 
test is positive, luteal support is continued up to week 10 pregnancy (week´12 gestation).  
If pregnancy is not confirmed on Visit 4 the early discontinuation visit should be 
performed including physical examination and vital signs. Blood samples will be taken 
for routine laboratory values.
•
At Visit 5 (Day 42 +/ 3 days – Week 6): Study medication packages should be returned. 
If pregnancy is confirmed according to clinical evidence then the new study medication 
packages will be dispensed. Pregnancy related TEAEs and concomitant medication will 
be recorded.
If an event of miscarriage occurs between the Visits 4 and 6, subject should return to the 
study site for the early discontinuation visit within 30 days of the last treatment dose or 
keep their appointment for Visit 6, whichever occurs first. A physical examination 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 20 of 54
including vital signs will be performed; blood samples will be taken for routine 
laboratory values. Concomitant medication and any TEAEs will be recorded; the subject
will return the remaining study medication.
•
End of treatment on Visit 6 (Day 70 +/- 3 days – Week 10): A transvaginal ultrasound 
examination will be performed to determine the pregnancy defined as the presence of 
fetal heart beats. Data on vital signs, routine laboratory values, TEAEs, and concomitant 
medication will be recorded. Subjects return their study medication.
•
Post treatment surveillance calls (Visit 7 and 8): Subjects will be followed during the 
pregnancy by routine pregnancy supervision program until the date of delivery. In 
addition 2 telephone calls (on Day 100 +/- 3 days and on Day 156 +/- 3 days) will be 
done to record any concomitant treatment and medications and any TEAEs. Especially 
events of miscarriage and preterm delivery will be recorded. 
•
After successful delivery (Visit 9), the time of delivery (pregnancy week) and the 
following parameters of the newborn(s) will be obtained: gender, APGAR Score, weight, 
height, head circumference, abnormal findings of physical examination.
•
At Visit 10 (Day 30 +/- 3 days after delivery): A phone call will be performed to record 
both mother’ and newborn’s safety and wellbeing.
4.2
Discussion of Study Design, Including the Choice of Control Groups
The aim of this study is to substantiate the empirical use of dydrogesterone in a prospective 
open-label, randomized clinical study. With this objective non-inferiority to the current 
standard of care should be demonstrated. Intravaginal progesterone gel, one of the current 
standard of care products for the luteal support in IVF, is included in this study as 
comparator. 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 21 of 54
5
SELECTION OF STUDY POPULATION
5.1
Inclusion Criteria
1. Signed informed consent
2. Premenopausal females, age > 18 years < 42 years
3. Non-smokers. For females who were past smokers, they must have stopped tobacco 
usage for at least 3 months prior screening visit
4. Early follicular phase (Day 2-4) FSH (Follicle stimulating hormone) less than or equal to 
15 IU/L and estradiol (E2) within normal limits at screening
5. LH (luteinizing hormone), PRL (prolactin), T (testosterone) and TSH (thyroid-
stimulating hormone), within the normal limits for the clinical laboratory, or considered 
not clinically significant by the Investigator within 6 months prior or at screening
6. Documented history of infertility (e.g., unable to conceive for at least one year or for 6 
months for women ≥ 38 years of age or bilateral tubal occlusion or absence)
7. Normal transvaginal ultrasound at screening (or within 14 days prior of screening)
without evidence of clinically significant abnormality consistent with finding adequate 
for ART with respect to uterus and adnexa (no hydrosalpinx or clinically relevant uterine 
fibroids)
8. Subject is not pregnant, confirmed by negative pregnancy test or by investigator 
judgment 
9. Clinical indicated protocol for induction of IVF with a fresh embryo
10. Single or dual embryo transfer
11. BMI ≥18 and ≤ 30 kg/m2
5.2
Exclusion Criteria 
1. Evidence of cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, 
hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), 
dermatologic/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, 
neurologic/psychiatric, allergy, recent major surgery (< 3 months), or other relevant 
diseases as revealed by history, physical examination and/or laboratory assessments 
which could limit participation in or completion of the study;
2. Acute urogenital disease
3. Known allergic reactions to progesterone products
4. Intake of any experimental drug or any participation in any other clinical trial within 30 
days prior to study start.
5. Mental disability or any other lack of fitness, in the Investigator's opinion, to preclude 
subjects in or to complete the study
6. Current or recent substance abuse, including alcohol and tobacco (Note: Patients who 
stopped tobacco usage at least 3 months prior to screening visit would be allowed)
7. History of chemotherapy 
8. Patients with more than 3 unsuccessful IVF attempts
9. Contraindication for pregnancy

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 22 of 54
10. Refusal or inability to comply with the requirements of the study protocol for any reason, 
including scheduled clinic visits and laboratory tests
11. History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages
5.3
Rationale for Diagnosis and Criteria
The evidence for the beneficial use of progesterone and other progestogens in treatment of luteal 
phase deficiency (LPD) is largely empirical.5 The range of success rates is between 30% and 
60%.6,7 The low success rates in some publications may at least partly be explained by the 
poor selection of cases with the diagnosis of luteal deficiency made in a haphazard manner. 
In addition, the doses might not always have been high enough.
When progestogen supplementation is the therapy of choice for IVF, then also dydrogesterone
could be used in infertility as it has no inhibitory effect on ovulation, does not inhibit the 
formation of progesterone in human placenta during early pregnancy, and does not cause 
masculinization of the fetus.8,9
The aim of this study is to substantiate the empirical use of dydrogesterone in a prospective 
open-label, two-arm, randomized clinical study. With this objective non-inferiority to the 
current standard of care should be demonstrated.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 23 of 54
6
REMOVAL OF SUBJECTS FROM THERAPY OR ASSESSMENT
All subjects are free to withdraw from participation in this study at any time, for any reason, 
specified or unspecified, and without penalty or loss of benefits to which the subject is 
otherwise entitled.
The Study Termination form must be completed for all subjects who have entered the study 
(i.e., have signed Informed Consent form), including subjects dropping out prior to any study 
drug administration.
In case of premature termination of the subject from the study, the primary reason for this 
premature termination is to be indicated according to the following definitions:
-
If pregnancy is not confirmed at Visit 4, the day of the biochemical pregnancy test 
(14 days after embryo transfer).
-
Adverse event: discontinuation due to any adverse event (AE) with a corresponding 
entry reflected on the Adverse Events form in the CRF
-
Lack of efficacy: subject fails to respond to the study drug at an acceptable level 
where the subject or the Investigator feels it is in the best interests of the subject to 
seek another treatment.
-
Lost to follow-up: the subject fails to return to the study site for scheduled visits and 
does not respond to telephone or written attempts to contact.
-
Withdrew consent: subject decides to stop her participation in the study for any 
reason other than an AE, or is unable to complete the study as described in the 
clinical study protocol (e.g., subject is relocating to another location).
-
Administrative: the Sponsor decides to terminate an individual subject or decides to 
discontinue the study (either at the study site or the entire study), e.g., general safety 
problems leading the Sponsor to entirely stop the study.
-
Protocol violation – anything which is in direct violation of the clinical study protocol 
(e.g., inclusion/exclusion violation).

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 24 of 54
7
TREATMENTS
The investigator receives the information of the treatment allocation number from the IRT
system. The subject will receive her study medication package from the study site or from the 
pharmacy of the institution.
7.1
Treatments to be administered
Luteal support starts on Day 0 (Visit 2), the day of oocyte retrieval. Subjects will be treated 
from Day 0 to Week 10 with any of the following two regimens:

Oral Dydrogesterone 10 mg tablets tid   or

Crinone 8%, intravaginal micronized progesterone gel 90 mg, once daily 
Treatment should we stopped at Visit 4 (Day 14 +/ - 3 days) if pregnancy is biochemically 
(β-hCG test) not confirmed. 
7.2
Packaging and Labeling
Packaging and labeling will be controlled by Clinical Supply Management (Drug Product 
Development) of Abbott Healthcare Products BV, Weesp, The Netherlands.
All packaging and labeling as well as the production of study drug will be in compliance with 
Good Manufacturing Practices (GMP) specifications, as mentioned in the Manufacturing of 
Investigation and Medicinal Products Volume 4 Annex 13 and in accordance with other 
applicable laws or local regulations.
Details on the packaging and labeling will be specified in the Packaging and Labeling 
Specifications and Supply Request.
An Abbott Qualified Person will release all the clinical supplies prior to shipment to 
investigational sites. A Certificate of Compliance will be issued stating the expiry date of the 
clinical supplies.
7.3
Storage and Dispensing of Study Drug
All clinical drug supplies are to be stored in a secure, monitored, limited-access area in 
accordance with labeled storage conditions. The temperature of the room should be below 25 
degrees C. Keeping the blister in the outer carton, in order to protect from moisture and light. 
The Investigator will maintain accurate records of the disposition of all clinical drug supplies 
received during the study. These records shall include the amounts of drug supplies and the 
dates on which drug supplies were received from the Sponsor (or an authorized 
representative), dispensed to the subject, returned by the subject and returned to the Sponsor 
(or an authorized representative). If errors or damages in the clinical drug supply shipments 
occur, the Investigator must contact the Sponsor (or an authorized representative) 
immediately.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 25 of 54
7.4
Method of Assigning Subjects to Treatment Groups
Subjects will be assigned to a treatment group using a centralized electronic system 
(interactive voice/web response system; IRT). The IRT assigns a 5-digit randomization 
number to each subject according to a randomization scheme. 
The randomization scheme will be provided by Clinical Supply Management (Drug Product 
Development) of Abbott Healthcare Products BV.
7.5
Selection of Doses in the Study
The selection of the doses of the treatment medication is based on the doses recommended by 
specialists for the treatment of luteal support in IVF and from published study reports.10
7.6
Selection and Timing of Dose for Each Subject
Subjects will be randomly assigned to a selected fixed dose regimen as described in 
Section 7.1. Subjects will start their treatment on the day of oocyte retrieval (Visit 2/Day 0) 
and if pregnancy is confirmed at Visit 4 (Day 14 +/- 3 days), treatment will be continued 
until Day 70. The dydrogesterone tablets will be taken orally evenly distributed over the day.
The micronized progesterone gel will be administered once daily via intravaginal application.
7. 7 
Blinding and Treatment Code Information
Not applicable
7.8
Prior and Concomitant Therapy
Any intake of further progesterone products during the treatment phase is not allowed and 
leads to the exclusion of the subject.
Any intake of other medication, which does not interfere with the study medication or its 
evaluation, is allowed as judged appropriate by the Investigator.
All medication taken by the subject during the study (from signing the informed consent 
form through post-study follow-up) will be recorded on the Concomitant Medication form, 
except for study drug.
7.9
Treatment Compliance
Drug Accountability
The Investigator is accountable for all clinical drug supplies shipped to his/her study site for 
the duration of the study. A final accounting of the clinical drug supplies will be required at 
the completion/termination of the study. The Investigator is required to provide written 
explanation for any discrepancies. All unused clinical drug supplies (except required 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 26 of 54
retention samples) will be inventoried and returned to the Sponsor (or an authorized 
representative) by a designated monitor. The Investigator will not be permitted to return or 
destroy (un)used clinical drug supplies or packaging materials unless authorized by the 
Sponsor (or authorized representative). The subjects should return their used/unused study 
medications to the pharmacy or study nurse. 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 27 of 54
8
STUDY ASSESSMENTS AND FLOW CHART
8.1
Efficacy Measurements
Pregnancy Rate
The primary efficacy parameter is the pregnancy rate defined as the presence of fetal heart 
beats at 12 weeks’ gestation determined by transvaginal ultrasound. 
Rate of successful completion of pregnancy
The secondary parameters are a positive pregnancy test on Day 14 after embryo transfer and 
the incidence of live birth and healthy newborns.
Status Newborn
Further secondary parameters are the incidence of life birth and healthy newborns. The 
gender and APGAR score will be recorded, as well as the height, weight and head 
circumference of the newborn.
In addition, a physical examination of the newborn will be performed and any malformations
will be recorded.
8.2
Safety Measurements
Adverse Events
Requirements for collecting, recording and reporting of AEs are described in Section 9. Each 
subject is to be evaluated at the termination visit. Should any AE be identified at this visit, 
the Investigator will continue to follow the subject as described in Section 9.1.2
Biochemical pregnancy
Is defined as a rise in β-hCG with no further clinical evidence of pregnancy at Visit 5 (Day 
42 -/+ 3 days) as determined and confirmed by investigator at the routine control. 
Miscarriage
Is defined as a pregnancy loss after the confirmation of pregnancy.
Routine laboratory
Blood will be collected for the determination of the following parameters: 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 28 of 54
Baseline routine laboratory values (hematology: hemoglobin, hematocrit, RBC count, WBC 
count, platelet count; biochemistry: glucose (if possible fasting), creatinine, alkaline 
phosphatase, total bilirubin, ALAT, ASAT, gamma-glutamyl transferase, uric acid, calcium, 
phosphate, potassium.
For subjects where the hormone values are not available prior screening a hormone testing  
including, FSH, estradiol (E2), LH (luteinizing hormone), PRL (Prolactin), T (testosterone) 
and TSH (thyroid-stimulating hormone) should be performed.  
Urine analysis (Dipstick)
Urine sample collection for routine urine analysis of pH, nitrite, specific gravity, blood, 
protein and glucose will be performed.
Urine sample collection for pregnancy test (strip test).
For values outside the normal range (or abnormal results) the clinical significance is to be 
judged by the Investigator.
Vital Signs
Height and weight must be recorded during the treatment phase. 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate are to be 
measured while the subject is in sitting position after 3-5 minutes rest.
Physical Examination
A physical examination should be performed and any relevant findings are to be recorded on 
the Medical History form in the CRF (for findings from the past that occurred prior to first 
screening visit), or on the Adverse Events form in the CRF for findings presently occurring. 
8.3
Other Assessments
Informed Consent
Voluntary written informed consent must be obtained from each subject (or their legally 
acceptable representative) prior to performing any study-related procedures (see Section 1.3).
Demographic Data
Demographic data (gender, date of birth, ethnicity, and race) will be collected for all subjects.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 29 of 54
Medical History
Any clinical event, including diagnosis, condition, or surgery, that occurred prior to the 
screening visit (before the informed consent is signed), is to be recorded on the Medical 
History form. In case a clinical event concerns a chronic disorder, which means it started in 
the past and it is still present at the screening visit, it should also be recorded on the Medical 
History Form. Examples of these events are diabetes, migraine, and hay fever.
Concomitant Medication
All medication taken by the subject during the study (from signing the informed consent 
form through post-study follow-up) is to be recorded on the Concomitant Medication form, 
except for study drug.
8.4
Appropriateness of Measurements
All measurements will be performed using standard methods which are generally recognized 
as being reliable, accurate, and relevant.
8.5
Primary Efficacy Variable
The primary efficacy parameter is the pregnancy rate defined as the presence of gestational 
sac(s) with viable fetal heart beats at 12 weeks’ gestation by transvaginal ultrasound.
8.6
Flow Chart of Study Assessments
All study assessments will be conducted as indicated in Table 1, which displays the 
frequency and timing of all measurements.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01,02 and 03
4 Januar y 2016
Confidential
Page 30 of 54
Table 1.
Flow Chart of Study Assessments
Period
Screening
and
Enrollment
Start of 
treatment
Day of 
oocyte 
Retrieval
Day of 
embryo
transfer 
(ET)
Day to 
confirm 
biochemical 
pregnancy
Day to 
confirm 
ongoing 
pregnancy
End of 
Treatment/ 
Early 
discontinuation
***
Post 
treatment 
surveillance 
calls every 2 
months 
After 
delive
ry 
Case 
notes
Phone 
call 30 
days 
after 
delivery
Visit
1
2
3
4**
5
6
7 + 8 
9
10
Day 
-40 to -1
0
2 to 5
16 to 19
42 (+/- 3 
days)
70 (+/- 3 days)
100 (+/- 3 days)
156 (+/- 3 days)
Informed consent
X
Demographic data
X
Medical history
X
Physical 
examination
X
X
Transvaginal 
ultrasound 
examination
X
X
should not be performed 
at the early 
discontinuation visit
Inclusion/exclusion 
criteria
X
Blood samples for 
routine laboratory 
values *
X
X
Serum β-hCG Test 
X
Urine analysis
X
X
X
β-hCG test (strip test)
X
Vitals signs
X
X

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01,02 and 03
4 Januar y 2016
Confidential
Page 31 of 54
Period
Screening
and
Enrollment
Start of 
treatment
Day of 
oocyte 
Retrieval
Day of 
embryo
transfer 
(ET)
Day to 
confirm 
biochemical 
pregnancy
Day to 
confirm 
ongoing 
pregnancy
End of 
Treatment/ 
Early 
discontinuation
***
Post 
treatment 
surveillance 
calls every 2 
months 
After 
delive
ry 
Case 
notes
Phone 
call 30 
days 
after 
delivery
Subject to collect 
study drug at 
pharmacy
X
X
X
Return unused 
medication
X
X
X
Concomitant 
medication
X
X
X
X
X
X
X
X
Compliance check
X
X
X
Adverse events
X
X
X
X
X
X
X
X
Infant 
assessment****:
gender, weight/ 
height, APGAR, 
physical 
examination
X
* For subjects where the hormone values are not available prior screening a hormone testing  including FSH, estradiol (E2), LH (luteinizing hormone), PRL 
(Prolactin), T (testosterone) and TSH (thyroid-stimulating hormone) should be performed. 
**if pregnancy is not confirmed on visit 4 an early discontinuation should be performed including physical examination and blood sampling for routine 
laboratory testing
*** If an event of miscarriage occurs between the Visits 4 and 6, patient should be return to the study site for the early discontinuation visit within 30 days of the 
last treatment dose or on their appointment for Visit 6, whatever occurs first. A physical examination including vital signs will be performed; blood samples will 
be taken for routine laboratory values

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01,02 and 03
4 Januar y 2016
Confidential
Page 32 of 54
**** After successful delivery, the time of delivery (pregnancy week) and the following parameters of the newborn baby will be obtained: gender, APGAR 
score, weight, height, physical examination.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 33 of 54
9
ADVERSE EVENTS
9.1
Adverse Events and Adverse Drug Reactions
Definition of Adverse Event 
Any untoward medical occurrence in a patient or clinical investigation subject administered a 
pharmaceutical product and which does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom (including an AE occurring from drug 
abuse, an AE occurring from drug withdrawal and any failure of expected pharmacological 
action), or disease temporally associated with the use of a pharmaceutical product, whether 
or not considered related to the pharmaceutical product.
An elective surgery/procedure scheduled to occur during a study will not be considered an 
adverse event if the surgery/procedure is being performed for a pre-existing condition and the 
surgery/procedure has been pre-planned prior to study entry.  However, if the pre-existing 
condition deteriorates unexpectedly during the study (e.g., surgery performed earlier than 
planned), then the deterioration of the condition for which the elective surgery/procedure is 
being done will be considered an adverse event.
Definition of Adverse Drug Reaction (ADR)
In the pre-approval clinical experience with a new pharmaceutical product or its new usages, 
particularly as the therapeutic dose(s) may not be established, all noxious and unintended 
responses to a pharmaceutical product related to any dose should be considered ADRs. The 
phrase “response to a pharmaceutical product” means that a causal relationship between a 
pharmaceutical product and an AE is at least a reasonable possibility, i.e., the relationship 
cannot be ruled out.
Regarding marketed pharmaceutical products: a response to a drug which is noxious and 
unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or 
therapy of disease or for modification of physiological function.
An unexpected ADR is an ADR, the nature or severity of which is not consistent with the 
applicable product information, such as the Investigator’s Brochure (IB) or the Summary of 
Product Characteristics (SPC).
9.1.1
Recording of Adverse Events
Any AE should be recorded on the Adverse Events form in the CRF and source documents. 
In order to avoid vague, ambiguous or colloquial expressions, the AE should be recorded in 
standard medical terminology rather than the subject’s own words. Whenever possible, the 
Investigator should group together into a single term signs and symptoms which constitute a 
single diagnosis.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 34 of 54
The existence of or change in an AE may be concluded due to the necessity to administer a 
concomitant medication, from a spontaneous report of the subject, from the physical 
examination or from special tests like ECG, EEGs, laboratory assessments or other study 
specified tests (source of AE).
AEs, which occur from the time the subject signed the study specific informed consent, 
regardless of the interval prior to the first administration of the study drug, and/or in the 
specified post-therapy AE collection period and/or in the post-protocol period until last visit 
will be handled as any other AE occurring during the treatment with study drug.
Each AE is to be evaluated for duration, severity, seriousness and causal relationship to the 
investigational drug. The action taken with study drug, the concomitant treatment/therapy 
introduced and the outcome as well as whether the event led to study termination will also be 
recorded.
Severity
The severity of the AE should be characterized as “mild, moderate or severe” according to 
the following definitions:
-
Mild events are usually transient and do not interfere with the subject’s daily 
activities.
-
Moderate events introduce a low level of inconvenience or concern to the subject and 
may interfere with daily activities.
-
Severe events interrupt the subject’s usual daily activity.
Drug-Event Relationship
The causal relationship between the study drug and the AE should be characterized according 
to the following:
-
Unrelated – there is not a reasonable possibility that the study drug caused the AE.
-
Unlikely – suggests that only a remote connection exists between the study drug and 
the event. Other conditions, including concurrent illness, progression or expression of 
the disease state or reaction to concomitant medication, appear to explain the AE.
-
Possible – suggests that the association of the AE with the study drug is unknown, 
however the event is not reasonably supported by other conditions.
-
Probable – suggests that a reasonable temporal sequence of the AE with drug 
administration exists and, in the Investigator’s clinical judgment, it is likely that a 
causal relationship exists between the drug administration and the AE, and other 
conditions (concurrent illness, progression or expression of the disease state, or 
concomitant medication reactions) do not appear to explain the AE.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 35 of 54
Outcome
The outcome of the adverse event should be classified according to the following definitions:
-
Recovered / resolved: the event has resolved (no further symptoms are present and no 
treatment is being received by the subject).
-
Recovered / resolved with sequelae: the event has resolved but there may be lingering 
effects present (e.g., a scar following a cut or abrasion).
-
Fatal: the subject died as a result of the event. This code should only be used for the 
event that caused the death, not any event that was present at the time of the subject’s 
death. Fatal events require immediately reporting to the Sponsor (or an authorized 
representative).
-
Unknown: may only be used in the event that the subject is lost to follow-up and no 
reliable data can be obtained.
All efforts should be made to classify the AE according to the above categories. Especially, 
an assessment of the drug-event relationship should be available from the reporter.
Note: when the AE is ongoing, the outcome will remain blank on the Adverse Events form in 
the CRF.
9.1.2
Follow-up of Adverse Events
All AEs occurring during the study are to be followed up in accordance with good medical 
practice until resolved or judged no longer clinically significant, or if a chronic condition, 
until fully characterized. All follow-up results are to be reported to the Sponsor (or an 
authorized representative).
9.2
Serious Adverse Events (SAEs) and Serious Adverse Drug Reactions
(SADRs)
Definitions of Serious Adverse Event (SAE) / Serious Adverse Drug Reaction (SADR)
Any untoward medical event that occur during any study phase at any dose:
-
results in death,
-
is life-threatening (an event in which the subject was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused death if it 
were more severe),
-
requires inpatient hospitalization or prolongation of an existing hospitalization,
-
results in persistent or significant disability/incapacity,
-
is a congenital anomaly/birth defect,
-
is considered an important medical event (an event that may not be immediately life-
threatening or result in death or hospitalization, but based on medical judgment may 
jeopardize the subject and may require medical or surgical intervention to prevent any 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 36 of 54
of the outcomes listed above (i.e., death of subject, life-threatening, hospitalization, 
prolongation of hospitalization, congenital anomaly, or persistent or significant 
disability/incapacity). Examples of such events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse as well as spontaneous or elective abortions, stillbirths and 
ectopic pregnancies).
9.2.1
Reporting Serious Adverse Events
Any SAE, whether or not related to the study drug, must be reported immediately (within 24 
hours of the investigator’s awareness of the event) by telephone or faxing the appropriate 
SAE forms to the numbers specified on each country specific SAE form.
9.2.2
Reporting of Suspected Unexpected Serious Adverse Drug Reactions
(SUSARs) to Regulatory Authorities and Investigators
Adverse reactions will be considered as unexpected if the nature, seriousness, severity or 
outcome of the reaction(s) is not consistent with the reference information. The expectedness 
of adverse reactions for this study is detailed for Dydrogesterone in the current Investigator 
brochure. For the comparative study drug, Crinone 8% intravaginal gel 90 mg, the reference 
safety information is the current SmPC issued in United Kingdom.
All SUSARs will be subject to expedited reporting. Additionally, post-study SUSARs that 
occur after the subject has completed a clinical study and are reported by the Investigator to 
the Sponsor (or an authorized representative) qualify for expedited reporting.
The Sponsor (or an authorized representative) is responsible for submitting reports of 
SUSARs to the appropriate national regulatory authorities within the required reporting 
period. All Investigators participating in ongoing clinical studies with the study drug will be 
notified by the Sponsor (or an authorized representative) of all SUSARs that require prompt 
submission to the IEC/IRB. The Sponsor (or an authorized representative) or the Investigator 
(according to national provisions) is responsible for notifying the IECs/IRBs in writing of the 
SUSARs within the required reporting timelines. Copies of the notification will be 
maintained by both the Investigator and the Sponsor (or an authorized representative) in the 
study documentation files.
Reports of miscarriage before presence of fetal heart beats at 12 weeks’ gestation (10 weeks´ 
pregnancy) primary endpoint efficacy; determined by transvaginal ultrasound) will be 
generally assessed (company assessment) with “no reasonable possibility” and as “expected” 
as it is awaited in the indication that less than 35% of the women will become pregnant 
(protocol: it is assumed that both dydrogesterone and micronized progesterone gel will have 
similar results with about 35% pregnancy rate at week 12).

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 37 of 54
9.2.3
Reporting of Pregnancy Adverse Event/Outcome
Pregnancy in a study subject is not considered an AE. However, all data regarding 
pregnancy, the evolution and the outcome, i.e., the health status of the newborn, have to be 
collected and documented in the CRF.
Any AE in the mother and/or fetus/newborn(s) (e.g. premature birth, low birth weight) 
should be checked for seriousness. Biochemical pregnancy as defined in section 8.2 is 
generally not considered a SAE. At least any complication of pregnancy after Visit 5 (Day 42 
+/- 3 days-Week 6: new study medication packages will be dispensed if patient pregnancy is 
ongoing) such as elective or spontaneous abortion, missed abortion, stillbirth, or congenital 
anomaly is considered a SAE and must be reported to the Sponsor (or an authorized 
representative) within 24 hours of the investigator becoming aware of the event and 
followed-up as described in Section 9.2.1. 
Without any complications (mother and/or child) hospital birth and prophylactic/elective 
caesarean section are generally not considered a reportable SAE. 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 38 of 54
10
STATISTICAL METHODS AND DETERMINATION OF SAMPLE 
SIZE
Data handling will be the responsibility of the CRO. The data will be inspected for 
inconsistencies by performing validation checks. Any inconsistencies found will be resolved 
by the monitor after contacting the Investigator. When the data in the database are considered 
clean and the subjects allocated to subject samples in a blind data review, the database will 
be locked to prevent unauthorized access. Next, the database will be made available as SAS®
files for statistical analysis.
All details regarding the statistical analysis and the preparation of tables, listings and figures 
will be described in the Statistical Analysis Plan prepared by the CRO and approved by 
Abbott before breaking the blind or database lock.
The statistical analysis will be performed by the CRO.
10.1
General Definitions and Conventions
Time-Related Definitions
All assessment dates will be related to the first day of study drug administration. This first 
day of drug administration is referred to as Day 0. 
The baseline period will be defined as the period from informed consent to the first study 
drug administration. The baseline value for a variable is defined as the last non-missing value 
collected before first study drug administration.
The endpoint value for efficacy variables is defined as the last non-missing value assigned to 
treatment for the subject.
All variables planned to be measured at one or more time points and supposed to be time-
related will be windowed.
Coding Systems
AEs and medical history Investigator terms will be assigned to a lowest level term (LLT) and 
a preferred term (PT) and will be classified by high level term (HLT), high level group term 
(HLGT) and primary system organ class (SOC) according to the MedDRA thesaurus.
Concomitant medications will be classified according to active drug substance using the 
WHO drug dictionary. The generic name, the preferred name and the WHO name will be 
assigned.
In addition, the Anatomical Therapeutic Chemical (ATC) classes will be assigned to the drug 
ID. ATC codes are defined to the 4th level. For each medication, the primary ATC class will 
be assigned manually based on the generic name and the reason for use.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 39 of 54
Default Summary Statistics
The default summary statistics for quantitative and ordinal variables will be the number of 
observations (n), mean, standard deviation (SD), median, minimum (Min) and maximum 
(Max) for subjects with data. Any other summary statistics will be described on an individual 
basis.
Default Frequency Tabulations
For qualitative variables, per category the numbers and frequencies of subjects with non-
missing data (n, %) will be the default summary presentation, and if appropriate and present, 
the number of missing values.
For AEs, medical history and concomitant medications, however, the denominator for the 
percentage calculation will be the number of subjects at risk for the particular treatment arm. 
A subject will be considered at risk if the subject is in the safety sample and entered the 
respective study period.
Subject Listings
Individual subject listings will be produced for all raw data and a selection of the derived 
data. 
10.2
Subject Samples
The main subject samples of interest are defined as follows.
The all subjects consented sample will consist of all subjects who:
-
Gave their informed consent.
The all subjects allocated to treatment sample will consist of all subjects who:
-
Were in the all subjects consented sample; and
-
Were allocated to treatment.
The safety sample will consist of all subjects who:
-
Were in the all subjects allocated to treatment sample; and
-
Had at least one dose of study medication administered.
The full analysis (FA) sample will consist of all subjects who:
-
Were included in the safety sample; and
-
Had data for at least one post-baseline assessment of any efficacy measurement. 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 40 of 54
The per-protocol (PP) sample will be defined through blind data review and will consist of 
all subjects who:
-
Were included in the FA sample; and 
-
Did not present any major protocol violation.
10.3
Efficacy
The primary efficacy parameter is the pregnancy rate defined as the presence of fetal heart 
beats at 12 weeks’ gestation by transvaginal ultrasound. The dydrogesterone group will be 
compared against the intravaginal micronized progesterone gel.
The primary endpoint is the comparison of ongoing pregnancy rates between the two
treatment groups. The primary efficacy analysis is using a two-sided 95% confidence interval 
with a non-inferiority margin of 10% for the difference in pregnancy rates in the two 
treatment groups. For the primary efficacy analysis, the full analysis (FA) sample will be 
used.
The following hypotheses are tested:
H0: pdydro – pcrinone ≤ -
H1: pdydro – pcrinone > -
Δ is clinically non-relevant difference accepted as the lower bound of non-inferiority.
In order to calculate the confidence intervals, a Cochran-Mantel-Haenszel test stratified for 
country and age groups will be used. Two age groups will be defined, subjects older or 
younger than 35 years. Mantel-Haenszel type estimators will be computed for the differences 
of proportions using Cochran’s weights. With n1 subjects in the dydrogesterone group and n2 
subjects in the comparator group within a given stratum, the weights for the stratum-specific 
proportion differences will be proportional to n1*n2/(n1+n2), and the variance of each 
stratum-specific proportion difference p1p2 will be estimated as 
p1(1p1) n1    p2(1p2) n2 .
The 95% confidence interval for the difference of pregnancy rates in each treatment group 
will be compared to Δ. In order to declare non-inferiority, the lower bound of the two-sided 
95% confidence interval should exclude a difference greater than 10% in favor of the 
comparator. If the hypothesis of inferiority can be rejected, a second hypothesis of 
superiority will be tested.
The following parameters will be analyzed as secondary efficacy variables:

chemical pregnancy rate (β-HCG test) on Day 14 after embryo transfer

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 41 of 54

abortion and preterm birth rates

incidence of live birth and healthy newborns.
The following parameters of the newborn will be analyzed:

APGAR score, as well as gender, height, weight and head circumference.

any malformations and abnormal findings of a physical examination of the newborn.
Further statistical tests may be performed on secondary variables. All efficacy and safety 
parameters will be summarized by standard descriptive methods.
An efficacy report will be written when all efficacy data are available and will be later 
included in the overall study report.
10.4
Safety
The safety sample will be used for the analysis of the safety and tolerability data. The safety 
and tolerability data collected during this study include vital signs, routine laboratory values 
and adverse events. Safety variables will be summarized by standard descriptive statistics. 
For concomitant medication, the WHO thesaurus will be used to assign them to a major 
therapeutic class. Adverse experiences will be classified by preferred term and body system 
according to the MedDRA dictionary.
An AE that starts during a unique treatment or that already exists before the start of that 
unique treatment but worsens during the treatment, including any subsequent wash-out or 
post-treatment period will be considered as treatment emergent for that unique treatment.
For the definition of treatment emergent, the following unique treatments are distinguished 
by applicable study period:

30 mg dydrogesterone

8% micronized progesterone gel 90 mg
AEs will be reported on a per-subject basis, i.e. counting subjects rather than events. This 
means that if a subject suffers the same AEs repeatedly during the applicable study period, 
the event will be counted only once for that period. Repeated events per subject will be 
summarized according to the following rule: if a subject suffered the same AE more than 
once, the event will be assigned the worst severity, the closest relationship to the study drug 
and the earliest starting date. Only treatment emergent AEs will be reported. In the listings, 
however, all occurrences of the AEs will be presented.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 42 of 54
For each unique treatment, treatment emergent AEs will be summarized per primary SOC, 
per HLT by primary SOC and per PT by HLT and primary SOC. Severity and drug-event 
relationship of treatment emergent AEs are summarized separately.
Vitals signs, including changes from baseline will be summarized. A frequency table will be 
presented for markedly abnormal values.
Laboratory variables, including changes from baseline will be summarized. A frequency 
table will be presented for markedly abnormal values. Shift tables will be presented 
according to the reference ranges (low, normal or high).
10.5
Other Assessments
The assignment of subjects to subject samples, the disposition of subjects with respect to 
premature termination, reason for premature termination, drug exposure and treatment 
compliance will be summarized per treatment group.
Demographics and other baseline characteristics will be summarized per treatment group.
Medical history, including coding data will be summarized per primary SOC, per HLT by 
primary SOC and per PT by HLT and primary SOC.
Major protocol deviations will be listed.
Concomitant medication, including coding data will be summarized per assigned treatment 
period for incidence per subject, for primary therapeutic subgroup (3rd level ATC code) and 
for generic name by therapeutic subgroup.
10.6
Subgroup Analysis
Subgroup analyses according to weight and race will be performed.
10.7
Interim Analysis
For this study, no interims analysis is planned.
.
10.8
Determination of Sample Size
Several studies can be found in literature investigating the use of dydrogesterone, micronized 
progesterone capsules (Utrogestan®) or micronized progesterone gel treatment (Crinone®) in 
IVF. The following table displays the 8- or 12-week pregnancy rate for several studies.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 43 of 54
8-week pregnancy rate
12-week pregnancy rate
Dydro-
gesterone
Intravaginal 
micronized 
progesterone 
capsules
micronized 
progesterone
gel
Dydro-
gesterone
Intravaginal 
micronized 
progesteron
e capsules
micronized 
progestero
ne gel
Ganesh 20113
29% 
(121/422)
23% 
(104/459)
29% 
(138/482)
Patki 200710
41% 
(150/366)
30% (91/309)
Kleinstein 200511
25% 
(55/218)
22% 
(47/121)
Tomic 201112
33% 
(62/185)
Simunic 200713
30% (42/136)
33% 
(43/130)
Ludwig 200214
17% (9/53)
25% 
(18/73)
Baruffi 200315
28% (29/103)
Pouly 199616
25% (36/144)
29% 
(40/139)
The largest study from Ganesh et al. showed comparable results for micronized progesterone 
gel and dydrogesterone and only a small, non-significant difference in rates between 
dydrogesterone and micronized progesterone capsules.3 Both the study from Kleinstein11 and 
Ludwig14 conclude that both micronized progesterone gel and micronized progesterone 
capsules will give similar results. Therefore, it is assumed that dydrogesterone and 
micronized progesterone gel will have similar results with about 35% pregnancy rate at week 
12.
A non-inferiority margin of 10% was chosen based on data from the previously approved 
Lutinus®/Endometrin® drug.17
Assuming a 35% pregnancy rate for the dydrogesterone and the micronized progesterone gel 
group, a sample size of about 479 subjects per group would provide 90% power to reject the 
null hypothesis of H0: pdydro – pcrinone ≤ -0.1 in favor of the alternative: H1: pdydro – pcrinone > -
0.1 with a one-sided significance level of 2.5%.
Assuming a dropout rate of 10%, a total sample size of 533 subjects per treatment group 
would be required, resulting in a total sample size of 1066 subjects in order to show 
non inferiority in the primary efficacy parameter.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 44 of 54
11
INVESTIGATOR OBLIGATIONS
The Investigator agrees to conduct the clinical study in compliance with this protocol after 
being approved by the IEC/IRB in compliance with local regulatory requirements. The 
Investigator and the Sponsor will sign the protocol to confirm this agreement.
11.1
Essential Study Documents
The Investigator is responsible for providing and maintaining essential study documents. 
Essential study documents are those documents that individually and collectively permit the 
evaluation of the conduct of the study and the quality of the data produced. These documents 
serve to demonstrate the compliance of the Investigator and the Sponsor (or an authorized 
representative) with the standards of GCPs and with all applicable national regulatory 
requirements.
Essential study documents will include regulatory documents as well as source documents 
which are original documents, data and records of clinical findings, observations and other 
activities in a clinical study necessary for the reconstruction and evaluation of the study. 
Source documents will include hospital records, clinical and office charts, laboratory notes, 
memoranda, subject diaries or evaluation checklists, pharmacy dispensing records, recorded 
data from automated instruments, copies or transcriptions certified after verification as being 
accurate copies, microfiches, photographic negatives, microfilm or magnetic media, x-rays, 
subject files and records kept at the pharmacy, at the laboratories and at medical/technical 
departments involved in the clinical study.
The Investigator agrees to allow direct access to all essential clinical study documents for the 
purpose of monitoring and/or auditing by the Sponsor (or an authorized representative) and 
inspection by the appropriate national and foreign regulatory authorities.
11.2
Case Report Form (CRF) Completion
Data reflecting the subject´s participation with the study drug under investigation will be 
reported to the Sponsor (or an authorized representative). The data will be recorded on the 
designated CRFs (paper or other media) provided or approved by the Sponsor. The CRF is 
essentially considered a data entry form and will not constitute the original (or source) 
medical records unless otherwise specified.
The Investigator will be required to submit a completed CRF for each subject who receives 
study drug, regardless of duration. 
For each subject that has signed the informed consent but does not qualify for allocation to 
treatment, i.e. Screen Failure, only the following information is required to be collected:
-
Informed Consent information
-
Reason for Termination information

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 45 of 54
-
Screen Fail Identifier question -YES/NO
-
Adverse Event information in case of a SAE reported to GPRM.
Electronic Data Capture (EDC) will be used for this trial, meaning that all CRF data will be 
entered in electronic forms at the investigational site. Data collection will be completed by 
authorized study site personnel designated by the Investigator. Appropriate training and 
security measures will be completed with the Investigator and all authorized study site 
personnel prior to the study being initiated and any data being entered into the system for any 
study subjects.
All data must be entered in English. The eCRFs should always reflect the latest observations 
on the subjects participating in the trial. Therefore, the eCRFs are to be completed as soon as 
possible during or after the subject´s visit. To avoid inter observer variability; every effort 
should be made to ensure that the same individual who made the initial baseline 
determinations completes all efficacy and safety evaluations. The Investigator must verify 
that all data entries in the eCRFs are accurate and correct. If some assessments are not done, 
or if certain information is not available or not applicable or unknown, the Investigator
should indicate this in the eCRF. The Investigator will be required to electronically sign off 
on the clinical data.
The monitor will review the eCRFs and evaluate them for completeness and consistency.  
The eCRF will be compared with the source documents to ensure that there are no 
discrepancies between critical data.  All entries, corrections and alterations are to be made by 
the responsible Investigator or his/her designee. The monitor cannot enter data in the eCRFs. 
Once clinical data of the eCRF have been submitted to the central server, corrections to the 
data fields will be audit trailed, meaning that the reason for change, the name of the person 
who performed the change, together with time and date will be logged. Roles and rights of 
the site personnel responsible for entering the clinical data into the eCRF will be determined 
in advance. If additional corrections are needed, the responsible monitor or Data Manager 
will raise a query in the EDC application.  The appropriate investigational staff will answer 
queries sent to the Investigator. This will be audit trailed by the EDC application meaning 
that the name of investigational staff, time and date stamp are captured.
The eCRF is essentially considered a data entry form and should not constitute the original 
(or source) medical records unless otherwise specified. Source documents are all documents 
used by the Investigator or hospital that relate to the subject´s medical history, that verify the 
existence of the subject, the inclusion and exclusion criteria and all records covering the 
subject´s participation in the study.  They include laboratory notes, ECG results, memoranda, 
pharmacy dispensing records, subject files, etc.  
The Investigator is responsible for maintaining source documents. These will be made 
available for inspection by the study monitor at each monitoring visit. The Investigator must 
submit a completed eCRF for each subject who receives study medication, regardless of 
duration. All supportive documentation submitted with the eCRF, such as laboratory or 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 46 of 54
hospital records, should be clearly identified with the study and subject number.  Any 
personal information, including subject name, should be removed or rendered illegible to 
preserve individual confidentiality.
Electronic case report form records will be automatically appended with the identification of 
the creator, by means of their unique UserID. Specified records will be electronically signed 
by the Investigator to document his/her review of the data and acknowledgement that the data 
are accurate. This will be facilitated by means of the Investigator’s unique UserID and 
password; date and time stamps will be added automatically at time of electronic signature. If 
an entry on an eCRF requires change, the correction should be made in accordance with the 
relevant software procedures. All changes will be fully recorded in a protected audit trail, and 
a reason for the change will be required.
11.3
Essential Records Retention
The Investigator should maintain the essential clinical study documents (including CRFs, 
source documents, clinical drug disposition records, signed subject informed consent forms, 
AE reports and other regulatory documents) as required by the applicable national regulatory 
requirements. The Investigator is to take adequate measures to prevent accidental or 
premature destruction of these documents. In the event of accidental destruction, the 
Investigator should notify the Sponsor (or an authorized representative) immediately.
Essential clinical study documents will be retained at least two (2) years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region OR at least two (2) years have elapsed 
since the formal discontinuation of clinical development of the investigational product. These 
documents shall be retained for a longer period, however, if required by the applicable 
regulatory requirements or by an agreement with the Sponsor (or an authorized 
representative).
The Investigator is required to notify the Sponsor (or an authorized representative) prior to 
changing the location or status of any essential clinical study documents. The Sponsor (or an 
authorized representative) will be responsible for informing the Investigator as to when these 
documents no longer need to be retained.
11.4
Investigator Agreement
The Investigator is responsible for assuring the proper implementation and conduct of the 
clinical study including those study-related duties delegated to other appropriately qualified 
individuals. The Investigator and his/her staff will cooperate with the Sponsor (or an 
authorized representative) during monitoring and auditing visits to assist with the review of 
the study data and resolve any discrepancies.
The Investigator will demonstrate due diligence in recruitment and screening of potential 
study subjects. The enrollment rate should be sufficient to complete the study as agreed with 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 47 of 54
the Sponsor (or an authorized representative). The Sponsor (or an authorized representative) 
is to be notified of any projected delays, which may impact the completion of the study.
The Sponsor retains the right to terminate the clinical study at any time for any reason. In 
such an event, instructions on the requirements for the discontinuation of subjects will be 
provided by the Sponsor (or an authorized representative).

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 48 of 54
12
SPONSOR OBLIGATIONS
12.1
Protocol Amendments
Only the Sponsor (or an authorized representative) will make modifications to the clinical 
study protocol, which will be documented in a written amendment that describes all changes 
that will be implemented. Protocol amendments will be categorized as either substantial or 
non-substantial.
Protocol amendments will be considered substantial when the changes have significant 
impact on:
-
The safety of physical or mental integrity of the subjects
-
The scientific value of the study
-
The conduct or management of the study
-
The quality or safety of any investigational medicinal product or control used in the 
study
Protocol amendments will be considered non-substantial when the changes affect only 
administrative issues with the conduct of the study, i.e., changes in telephone numbers or 
addresses.
The Sponsor (or an authorized representative) will be responsible for notifying the 
appropriate national regulatory authorities in writing of any amendments to the protocol prior 
to the changes being implemented except in those cases where the changes are necessary to 
eliminate an immediate hazard to the clinical study subjects.
Substantial amendments will require written approval by the IEC/IRB prior to being 
implemented by the Investigator at the study site except under those circumstances described 
previously. Non-substantial amendments will not require approval by the IEC/IRB unless 
requested by the IEC/IRB.
12.2
Study Monitoring
The study will be monitored by authorized representatives of the Sponsor throughout its 
duration by means of personal visits to the Investigator’s facilities and through other 
communications (e.g., telephone calls, written correspondence). Monitoring visits will be 
scheduled at mutually agreeable times periodically throughout the study and at frequency 
deemed appropriate for the study. 
These visits will be conducted to evaluate the progress of the study, ensure the rights and 
well-being of the subjects are protected, check that the reported clinical study data are 
accurate, complete and verifiable from source documents, and the conduct of the study is in 
compliance with the approved protocol and amendments, GCPs and applicable national 
regulatory requirements. A monitoring visit will include a review of the essential clinical 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 49 of 54
study documents (regulatory documents, CRFs, source documents, drug disposition records, 
subject informed consent forms, etc.) as well as discussion on the conduct of the study with 
the Investigator and staff. The Investigator and staff should be available during these visits to 
facilitate the review of the clinical study records and resolve/document any discrepancies 
found during the visit.
12.3
Quality Assurance Audits
The Sponsor’s (or an authorized representative’s) Quality Assurance department may 
conduct on-site audits of all aspects of the clinical study either during the study or after the 
study has been completed.
The clinical study may also be subject to inspection by regulatory authorities (national or 
foreign) as well as the IECs/IRBs to ascertain that the study is being or has been conducted in 
accordance with protocol requirements, GCPs, as well as the applicable regulatory 
requirements.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 50 of 54
13
PUBLICATION POLICY
The data generated by this study are confidential information of the Sponsor. The Sponsor 
will publicly disclose the results of all applicable clinical trials following legal and regulatory 
requirements.  The publication policy with respect to the Investigator and study center will be 
set forth in the Clinical Trial Agreement.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 51 of 54
14
INSURANCE
The Sponsor has taken out a liability insurance, which covers this study as required by local 
law and/or national regulations and/or ICH guidelines whichever is applicable. 

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 52 of 54
15
REFERENCES
1. Mouzon J; Lancaster P, Nygren K et al: World collaborative Report on Assisted 
Reproductive Technology, 2002. Hum Reprod 2009: 24 (9) 2310-2320.
2. Jones GE. Some newer aspects of management of infertility. J Am Med Assoc 
1949;141(16):1123-29, illust.
3. Ganesh A. et al: Comparison of oral dydrogesterone with progesterone gel and 
micronized progesterone for luteal support in 1,373 women undergoing in vitro 
fertilization: a randomized clinical study. Fertility and Sterility, 2011, May; 95(6): 1961-5
4. Soliman S; Daya S, Collins J, Hughes, EG. The role of luteal phase support in the 
infertility treatment: a meta-analysis of the randomized trails. Hum Reprod 
2002;17:2287-99
5. Sauer MV. Use of progesterone in assisted reproduction. J Reprod Med 1999;44 Suppl 
2:197-202
6. Gellé P, Schaeffer Ph. Apropos of the use of dydrogesterone in gynecology and 
obstetrics; clinical experience [French]. Bull Fed Soc Gynecol Obstet Lang Fr.
1965;17(4):369-70.
7. Taubert HD. Jürgensen O, Becker H. Clinical observations on luteal phase inadequacy. 
Bull Schweiz Akad Med Wiss 1969;25(4-6):586-94
8. Wesselius-DeCasparis A, Duphaston. Revised summary of pharmacological properties 
and clinical results, 1971, Abbott report
9. Saure A, Teräväinen T, Karjalainen O. The effect of synthetic gestagens on progesterone 
formation in vitro in human placenta of early pregnancy. J Reprod Fertil. 1977;51(2):369-
73.
10. Patki A, et al: Modulating fertility outcome in assisted reproductive technologies by the 
use of dydrogesterone. Gynecological Endocrinology, October 2007; 23 (S1): 68-72 
11. Kleinstein et al: Efficacy and tolerability of vaginal progesterone capsules compared to 
progesterone gel for luteal phase support during assisted reproduction, 2005. Fertility and 
Sterility, 83 (6) 1641-1649
12. Tomic V et al: Oral micronized progesterone combined with vaginal progesterone gel for 
luteal support, 2011. Gynecological Endocrinology 27(12): 1010-1013
13. Simunic V et al: Comparative study of the efficacy and tolerability of two vaginal 
progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal 
support 2007 Fertility and Sterility, 87 (1) 83-87

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 53 of 54
14. Ludwig M et al: Luteal support using either Crinone 8% or Utrogest: results of a 
prospective, randomized study, 2002. European Journal of Obstretics & Gynecology and 
Reproductive Biology 103: 48-52
15. Baruffi R et al: Effects of Vaginal Progesterone Administration Starting on the Day of 
Oocyte Retrieval on Pregnancy Rates, 2003. Journal of Assisted Reproduction and 
Genetics 20 (12), 517-520
16. Pouly JL et al: Luteal support after in-vitro fertilization: Crinone 8%, a sustained release 
vaginal progesterone gel, versus Utrogestan, anoral micronized progesterone, 1996. 
Human Reproduction 11 (10): 2085-2089.
17. Center for drug evaluation and research, medical review 22-057.

Abbott Laboratories GmbH
Protocol M13-625
Working Protocol including amendment 01, 02 and 03
4 January 2016
Confidential
Page 54 of 54
16
APPENDICES
16.1
Appendix – Participating Countries’ National Insurance Requirements
Not part of the protocol
16.2
Appendix – Coordinating Investigator Signature of Clinical Study Report
The following Investigator is regarded to be the coordinating Investigator who should sign 
the Investigator signature page of the clinical study report:
<insert name or define the process of designating the signatory coordinating Investigator>.